Newly-identified protein may contribute to colon cancer development
the ONA take:
A newly-identified pathway may contribute to the development of colon cancer, according to a study published in PLoS Genetics.
Researchers led by Anil Rustgi, MD, of the Perelman School of Medicine at the University of Pennsylvania conducted a follow-up to a 2013 study that identified the LIN28B protein as a contributor of cancerous growth in intestinal cells through suppression of Let-7 molecules.
In the new study, the researchers created transgenic mice that produced no Let-7 miRNAs in order to better understand their function in preventing cancer.
They found that adenomas adenomatous polyps, as well as adenocarcinomas that resembled human colon tumors, had formed in the intestines of all these mice without Let-7 by mid-adulthood.
Upon analyses of the tumors, they were able to identify a protein called Hmga2 as a major factor in their development. They were able to conclude that within the intestinal lining of the mice without Let-7, Hmga2 gene expression was unusually high.
In order to check the relevance of these findings, the researchers also examined several hundred human colorectal cancer samples and found lower-than-normal Let-7 miRNA as well as higher-than-normal HMGA2 (the human version of the mouse Hmga2 protein) expression.
A newly-identified pathway may contribute to the development of colon cancer.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Palliative Cancer Care Should Focus on Symptoms, Not Diagnoses
- COX-2 Inhibitors Can Improve Response to Immunotherapy of Some Cancer Tumors
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|